VHL and renal cell carcinoma: Emerging studies using ctDNA have begun to detect these mutations non-invasively: targeted sequencing panels covering hundreds of cancer-related genes have successfully identified VHL, PBRM1, and BAP1 alterations in plasma samples from patients with metastatic RCC, with concordance rates up to 77% compared to matched tissue samples [81,82].